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546Inhibition of Cathepsin S Reduces Allogeneic T Cell
Priming but Not Graft-versus-Host Disease Against
Minor Histocompatibility Antigens
Hisaki Fujii,1 Sabine M. Ivison,2 Hiromi Shimizu,3 Ryosuke Kajiwara,4 Amina Kariminia,2
Matthew Yan,5 Jan P. Dutz,6 Kirk R. Schultz2Cathepsin (Cathepsin) S, L, and B proteases mediate antigen presentation on major histocompatibility com-
plex (MHC) class II by degrading the invariant chain Ii, which blocks peptide loading. The ability of the
Cathepsin S inhibitor LHVS (morpholinurea-leucine-homophenylalanine-vinylsulfone phenyl) to impede an-
tigen presentation has led its development as a therapy for autoimmune diseases. There is substantial evi-
dence that donor T cell recognition of host minor histocompatibility antigens (miHA) and subsequent
destruction of host tissue mediates graft-versus-host disease (GVHD). We hypothesized that enzymes in-
volved in antigen presentation may play a role in the development of GVHD. Using the C57BL/6/ BALB.B
minor mismatch acute GVHD (aGVHD) model, we found that the cathepsin S activity of spleens from allo-
genetically transplanted mice were significantly increased 1 week after transplantation compared with syn-
geneic mice. Although LHVS decreased T cell priming responses against both single OVA antigen and miHA
in vitro, LHVS did not reduce the severity of aGVHD. In fact, LHVS exacerbated a CD41-T cell-dependent
model of GVHD similar to chronic GVHD. This suggests that cytokines rather than T cells may mediate much
of the damage in the aGVHD model and that therapeutics based on inhibition of antigen presentation for
GVHD must be approached with caution.
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Graft-versus-host disease (GVHD), secondary to
T cell recognition of host minor histocompatibility an-
tigens (miHA), is a major complication of blood and
marrow transplantation (BMT). Although the stan-
dard treatment for this disease is immunosuppression,1Division of Clinical Pharmacology and Toxicology,
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6/j.bbmt.2011.11.027the tendency of immunosuppressive agents to target
T cells can lead to severe infections. Another approach
is to utilize drugs with selective effects on antigen-
presenting cells (APCs), thereby decreasing their abil-
ity to present antigen to and activate host-reactive
T cells. In this regard, the 4-aminoquinolines,
chloroquine, and hydroxychloroquine, block major
histocompatibility complex (MHC) class II antigen
processing and presentation in vitro. We have previ-
ously shown that chloroquine treatment of mice leads
to decreased T cell responses and lowered incidence of
GVHD [1,2]. Chloroquine derivates are nonspecific;
they raise endosomal pH, disrupting multiple
endosomal enzymes and protein interactions [3,4]
including antigen-processing proteases and Toll-like
receptor (TLR)-ligand interactions. Chloroquine-
mediated inhibition of GVHD may therefore work
by downregulation of MHC II-mediated antigen pre-
sentation or by inhibiting TLR9 signaling, as the latter
has been implicated in the pathology of GVHD [5].
However, phase III clinical trials have shown that chlo-
roquine is not better than cyclosporin plus steroid at
treating established GVHD [6,7]. A specific inhibitor
of antigen presentation, given prophylactically, may
be a more effective alternative to chloroquine.
Biol Blood Marrow Transplant 18:546-556, 2012 547Inhibition of Cathepsin S and Allogeneic T Cell Priming in GVHDAfter the invariant chain (Ii) binds to MHC class
II molecules in the endoplasmic reticulum, the com-
plex is transferred to endosomes where the acidic en-
vironment activates proteases such as cathepsin L, B,
and S that cleave Ii. The truncated form of Ii is still
able to reduce the association of other peptides with
the MHC II complex until after Cathepsin S converts
it to class II-associated invariant chain peptide
(CLIP). With the help of the MHC II-like molecule
DM, CLIP can then be displaced by degraded anti-
gen, after which the MHC II/antigen complex is
transported to the cell surface. By controlling the
pace of Ii degradation, Cathepsin S is thus able to in-
fluence the rate of MHC class II-mediated antigen
presentation [8-10].
In mice, cathepsin S is active in professional
antigen-presenting cells such as dendritic cells, B cells,
and macrophages [8], whereas cathepsin L is active in
thymic epithelial cells [11]. In humans and mice, ca-
thepsin S also processes antigen in nonprofessional
APCs [11,12]. Cathepsin S has been shown to be
involved in the presentation of endogenous antigens
such as IgM, b2-M, or Ea52-68 [8,13].
LHVS (morpholinurea-leucine-homopenylala-
nine-vinylsulfone phenyl) inhibits cathepsin S activity
[14,15] by direct interaction [16] with therapeutic ef-
fects on autoimmune diseases [8,17], whereas other
cathepsin S inhibitors show potential as a therapeutic
strategy for a mouse model of Sj€ogren syndrome [18].
In mixed lymphocyte responses, proliferation of I-Ad
splenocytes in response to stimulationwith splenocytes
of cathepsin S2/2 I-Ab mice was reduced by 50% com-
pared with cathepsin S1/1mice [10]. However, the ex-
tent of Cathepsin S involvement on antigen processing
is likely to be both haplotype- and peptide-dependent
[9]. T cells are unaffected by LHVS treatment, as
spleen cells from mice treated with LHVS exhibit a
normal response to heterologous spleen cells [17]. Al-
thoughLHVS inhibition of cathepsin S in autoimmune
disease models shows decreased self-antigen-specific
T cell proliferation, little is known about its effect on
presentation of alloantigens and impact on tissue
rejection as seen in acute or chronic forms of GVHD.
We hypothesized that suppression of the MHC class
II processing pathways by cathepsin inhibition would
reduce GVHD. To investigate this, we used a lethal
GVHDmousemodel based onminor histocompatibil-
ity mismatches. We found significant elevation of
cathepsin S activity at day 7 and cathepsin L/B activity
at day 14 in allogeneic mice compared with syngeneic
control after transplantation, suggesting that cathepsin
S, L, and B may be required for miHA antigen pro-
cessing in this model. Although LHVS-mediated
Cathepsin S inhibition decreased both presentation of
exogenous OVA antigen and presentation of endoge-
nous MiHA, it did not inhibit lethal GVHD in an
acute model. Interestingly, LHVS treatment exacer-bated a CD41-dependent model of chronic GVHD
(cGVHD)-like disease.MATERIALS AND METHODS
Mice
Five- to 6-week-old C57BL/6 (B6; H-2b) and
C.B10-H2b/LiMcdJ (BALB.B (BB); H-2b) mice were
obtained from The Charles River (Wilmington,
MA) and Jackson Laboratories (Bar Harbor, ME).
Mice were maintained as a breeding colony at the
Child and Family Research Institute, Vancouver,
Canada, housed under specific pathogen-free condi-
tions in microisolators. All experiments were per-
formed in accordance with the Canadian Council on
Animal Care guidelines andwith institute review board
approval. OT-II TCR transgenic mice [19] weremain-
tained by Dr. Dutz (UBC, Vancouver, Canada).
Reagents
LHVS, an irreversible, specific cathepsin S inhibi-
tor was a gift from Arris Pharmaceuticals (South
San Francisco, CA), and stock solutions were made
in vehicle. LHVS was tested negative for endotoxin
contamination with Limulus Amebocyte Lysate
PYROGENT Plus (Cambrex Bio Science,Walkers-
ville, MD).
Measurement of Endogenous Cathepsin Activity
Spleen and lymph nodes from C57BL/6 mice
were used to determine cathepsin S, B, and L activity,
as previously described [18]. Briefly, tissues were gently
homogenized in 0.25 M cold sucrose and spun down
at 1,080 g for 20minutes at 4C.The collected super-
natant was centrifuged at 25,000  g for 30 minutes
at 4C, and the resulting pellet was suspended in
50 mM acetate buffer (pH 5.0) for cathepsin B and L
or in 0.1 M potassium phosphate buffer (containing
5 mM EDTA-2Na, 5 mM DTT and 0.01% Triton
X-100, pH5 6.5) for cathepsin S. After the suspension
fluid was freeze-thawed three times to disrupt lyso-
somal membranes, the fluid was centrifuged at 25,000
for 20 minutes at 4C, and the supernatant was used
as the lysosome fraction. The isolated lysosome frac-
tion was preincubated with specific inhibitors (CA074
Peptide International, California; Z-FY(t-Bu)DMK;
Calbiochem, San Diego, CA) for 5 minutes for cathep-
sin B and cathepsin L, 45 minutes for cathepsin S
at 37C, and the fluorescence was then measured with
Z-Phe-Arg-methyl coumarylamide as a substrate (final
10 mM; Peptide International, Louisville, KY) for
cathepsin B and L and with Z-Val-Val-Arg-methyl
coumarylamide (final 5 mM) for cathepsin S. The fluo-
rescence of the liberated 7-amino-4-methylcoumarin
was measured by fluorescence spectrophotometer,
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unit of enzyme was defined as the amount, which de-
graded 1 mmol of substrate per minute.
In Vivo Treatment with a Cathepsin S-Specific
Inhibitor
Mice were given either LHVS or vehicle by i.p. in-
jection at different concentrations (50 or 100 mg/kg)
for 2 weeks (three times per week). Spleen and lymph
nodes were used for cathepsin L, cathepsin B, and ca-
thepsin S assays.Mice undergoing BMT in theGVHD
models were given inhibitor or control three times
weekly i.p. starting 2 weeks before BMT until the
end of the experiment.
Proliferation Assay
For CD3 monoclonal antibody (CD3mAb) stimu-
lation, 96-well plates were coated with anti-CD3mab
(10 mg/mL) and incubated at 37C for 90 minutes
before washing. C57BL/6 splenocytes (2  105/well)
were cultured in the coated plates with LHVS or vehi-
cle for 24 hours before pulsing with 1.0 mCi [3H]thy-
midine (Amersham, Oakville, Ontario, Canada) for a
further 18 hours.
For measurement of ovalbumin-mediated stimula-
tion, CD41 T cells (5  104/well) were purified from
OT-II splenocytes by negative selection as follows:
CD8, CD11b (Mac-1), CD45R/B220, Ly-6G/C
(Gr-1), and TER119-expressing cells were removed
by the CD41 T Cell Enrichment Kit StemSep
Mouse from StemCell (Vancouver, Canada). These
CD41Tcells were combinedwith dendritic cells (DC)
isolated by positive selection of CD111c (EasySep,
StemCell Technologies Inc.) from splenocytes (5 
104/well) of C57BL/6 mice treated with 50 or
100 mg/kg of LHVS or the equivalent volume of vehi-
cle three times per week for 2 weeks. The mixed cul-
tures were incubated with ovalbumin protein (100
mg/mL) or OVA323–339 peptide (1 mg/mL) for 72 hours
and then pulsed with [3H]thymidine for another 18
hours. DNA was then harvested using a Mach III M
harvester (Tomtec, Hamden, CT), and [3H] thymidine
incorporation was counted on a 1450Microbeta liquid
scintillation counter (Wallac Trilux, Turku, Finland).
Cytokine Production
Plasma was collected from syngeneic and alloge-
neic mice at day 7 and day 14 after transplantation
and stored at280Cuntil analysis. Interferon (IFN)-g,
tumor necrosis factor (TNF)-a, and interleukin (IL)-6
levels were determined using the mouse inflammation
cytometric bead array (CBA) kit (BD Pharmingen,
SanDiego,CA) following themanufacturer’s protocol.
OT-II LN cells (1  106/well) and irradiated
C57BL/6 splenocytes (1 106/well) frommice treated
with LHVS (100 mg/kg) or vehicle were cultured withOVA protein (100 mg/mL) or OVA323–339 peptide
(1 mg/mL) for 72 hours at 37C in a 24-well plate in
10% RPMI media. The supernatant was collected
24 hours after incubation; IL-2 and IFN-g levels
were measured by ELISA (BD Pharmingen). Samples
and standards were run in duplicate.
T Cell Priming for Minor Histocompatibility
Antigens and Proliferation Assay
C57BL/6 mice were administered LHVS
(100 mg/kg) or vehicle three times weekly for 2 weeks,
followed by two intraperitoneal injections of 2.5 107
BALB.B splenocytes.
After injection of LHVS or vehicle for another 4
to 8 weeks (three times weekly), responder C57BL/6
splenocytes (4  105 cells/well) were cultured in a
96-well plate in 10% RPMI media with mitomycin
C-treated stimulator BALB.B splenocytes at an R:S
ratio of 1:1, 2:1, 4:1 for 96 hours and then pulsed
with 1.0 mCi [3H]thymidine for another 18 hours.
Data are presented as the mean difference, with stan-
dard error of the mean (SEM) bars in stimulated and
unstimulated cultures (DCPM).
BMT
Acute GVHD (aGVHD) model: recipient
BALB.B female mice between 8 to 12 weeks were irra-
diated at 680 cGy (300 kV; 2 Gy/min) before injection
with 8 106 BM and 2 107 spleen cells fromC57BL/
6 female mice within 24 hours. In the second GVHD
model, which resembles cGVHD, recipient BALB.B
female mice were injected with either 5  106 T cell-
depleted bone marrow (TCD-BM) or TCD-BM cells
plus 1-2  106 naive CD4 (CD62Lhigh CD442/low
CD252) T cells. Naive T cells were isolated by flow-
cytometric sorting as described in the information to
follow. T cells were depleted from bone marrow using
biotinylated anti-Thy1.2 antibody (EasySep, StemCell
Technologies Inc.). Evaluation of GVHD was based
on well established criteria consisting of several cate-
gories: overall ill appearance (hunching, ruffled fur),
wasting, fur loss, and wrinkling of the skin. Disease
was quantified in the acute model by scoring from
0 to 2 in all categories as previously described [20].
To quantitate disease in the cGVHD-like model,
mice were scored blindly as follows: 0, healthy; 1,
skin lesions with alopecia less than 1 cm2; 2, skin le-
sions with alopecia 1 to 2 cm2; 3, skin lesions with al-
opecia more than 2 cm2. Additionally, the mice were
assigned 0.3 points each for skin disease (lesion or scal-
ing) on the ears, tail, and paws (0-3.9 points) three
times per week according to established protocols
[20,21]. Mice were sacrificed if their weight dropped
below 20% of their starting weight according to
criteria established by the University of British
Columbia Ethical Review Committee.
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Cells pooled from spleen and lymph nodes were
first stained with Cy-Chrome–conjugated antimouse
CD4 (RM4-5), fluorescein isothiocyanate (FITC)-
conjugated anti-CD25 (7D4), APC-conjugated anti-
CD44 (IM7), and phycoerythrin (PE)-conjugated
anti-CD62L (MEL-14). All antibodies were purchased
fromBDPharmingen (San Jose, CA). The stained cells
were sorted into naive (CD62LhighCD442/low)
CD252CD41 T cells using a FACS Aria equipped
with FACSDiva software (Becton Dickinson, San
Jose, CA). The purity of positively selected naive
CD41 T cells was .97%.
Flow Cytometric Analysis
Four-color flow cytometry was performed on
a FACSCalibur flow cytometer (Becton Dickinson).
For analysis of cell surface molecules, samples were la-
beled with directly conjugated fluorescent antibodies
at 4C for 30 minutes. The samples were then washed
and suspended in 1.5% paraformaldehyde and ana-
lyzed within 24 hours. All antibodies were obtained
from BD Pharmingen (San Diego, CA). Relevantly
labeled isotype control antibodies were included in all
experiments. Analysis was performed using FLOWJO
software (Tree Star, San Carlos, CA).
Engraftment
Marker D8Mit224 was used for detection of donor
cells in the C57BL/6 / BALB.B transplantations.
Polymerase chain reaction (PCR) was run with 250
ng of genomic DNA in 25-mL reaction volumes for
40 cycles.
Quantitative PCR
Expression levels of cathepsin S and internal
reference 18sRNA was measured by quantitative
PCR (qPCR). Total RNA was extracted from sorted
macrophages (CD11b1CD11c2), dendritic cells
(CD11b6CD11c1), and B cells (B2201CD11c2) us-
ing Trizol reagent (Gibco BRL, Rockville, MD). Be-
cause of the scarcity of dendritic cells, myeloid and
lymphoidDCwere analyzed together as total dendritic
cells. cDNAwas synthesized with equal amounts of to-
tal RNA using oligo dT primers and Superscript II
reverse transcriptase (Invitrogen Life Technologies,
Carslbad, CA). Real-time qPCR was performed using
the Lumix system (Invitrogen Life Technologies).
Amplification and product detection was performed
using an ABI PRISM 7000 Sequence Detection
System (Applied Biosystems) as recommended by the
manufacturer. The quantity of cDNA for each RNA
sample was normalized to the quantity of 18sRNA
cDNA in each sample, and relative expression was de-
termined using the DDCt (threshold cycle) method
according to the manufacturer’s protocol. LUX Fluo-rogenic Primer (Invitrogen Corp.) specific for each
mRNA was designed using Invitrogen’s D-LUX De-
signer Software. Cathepsin S was assayed in triplicate
using the following primers (FAM-labeled Lux primer;
Invitrogen) F: 50-GCAGACGCTTCCTATCCCTAC
AA-30, R:50-GGAGCTGAATGTACCTTGAACA-30.
The FAM-labeled mouse 18sRNA Certified LUX
PrimerSet (Invitrogen)was used to amplify the controls.
Statistical Analysis
Survival curves were plotted using Kaplan-Meyer
estimates and analyzed by log-rank test. For statistical
analysis, the Mann-Whitney U-test was used, except
for the results presented in Figures 1C and 2 that
were analyzed using the paired t-test. All results are
presented as mean 6 standard error (SE). Descriptive
statistics were generated on all data using Prism ver-
sion 4 for PC (GraphPad Software, San Diego, CA).RESULTS
Cathepsin S Activity in an miHA Mismatched
GVHD Murine Model
To assess the role of cathepsin S in the develop-
ment of GVHD, we first evaluated cathepsin activities
in the spleen and lymph nodes from mice transplanted
withmiHA disparate (B6/BB) and syngeneic (BB/
BB; negative control) donor cells. As shown in
Figure 1A, splenic cathepsin S activity in mice receiv-
ing MiHA disparate (C57BL/6) donor cells was signif-
icantly higher thanmice receiving syngeneic (BALB.B)
donor cells 7 days after transplantation (mean6 SEM,
174.0 6 16.9 versus 49.7 6 17.0 mU/mg protein, P\
.01). At 14 days posttransplantation, there is no signifi-
cant difference in cathepsin S activity. In contrast,
cathepsins B and L were not different at the 7-day
time point but showed increased activity in the spleen
14 days after transplantation (Figure 1B and C). (Syn-
geneic versus MiHA disparate activities: cathepsin B is
656.5 6 61.4 versus 2292.0 6 103.9 mU/mg
protein; P\ .01; cathepsin L is 9.16 3.7 versus 33.56
3.5 mU/mg protein; P\ .01).
Because we used total splenic cells as a source of ca-
thepsins, and cathepsin S is expressed in several types
of APCs such as B cells, DCs, and macrophages, we
sought to determine if one particular type of APC
was the source of increased cathepsin S activity at
day 7 after allogeneic transplantation. Determination
of absolute B cell, DC, and macrophage populations
in the spleen at day 7 showed that although all popula-
tions increased after allogeneic compared with synge-
neic transplantations, macrophages were the most
numerous APC population in allotransplanted mice
at day 7 (Figure 1D). qPCR analyses showed that rel-
ative cathepsin S mRNA levels were 1.9, 4.5, and 5.8
times higher in macrophages, B cells, and DC
Figure 1. Endogenous splenic Cathepsin S activity after transplantation. (A-C) Splenic Cathepsin S, B, and L activities were determined 7 and 14 days
posttransplantation. (D) Total numbers of B cells (B2201CD11c2), DCs (CD11c1), and macrophages (Mac, CD11b1CD11c2) in the spleen were de-
termined at day 7 posttransplantation. (E) Also at day 7 posttransplantation, FACS-sorted splenic B cells, macrophages (CD11b1CD11c2), and DCs
were analyzed for relative cathepsin S mRNA levels by quantitative PCR. Data are expressed as a ratio of mRNA relative to 18sRNA. (F and G) Surface
marker analysis of lymphoid (CD11b2CD11c1) and myeloid (CD11b1CD11c11) splenic dendritic cells from transplanted mice. MFI, mean fluorescent
intensity. All results are representative of three independent experiments. Black bar (BB/ BB) indicates mice receiving syngeneic donor cells, whereas
white bar (B6/ BB) indicates mice receiving allogeneic donor cells. The data show mean 6 SEM. *, **, *** indicates P\.05, .01, .001, respectively.
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mice compared with mice receiving syngeneic donor
cells (Figure 1E), suggesting that all APCs were con-
tributing the increased cathepsin S activity at day 7.
Flow cytometric analyses showed that CD86 and/or
MHC class II (I-Ab) expression on DCs were upregu-
lated in mice receiving allogeneic donor cells com-
pared with control. Lymphoid DCs showed an
increase in both CD86 and MHC II expression
(Figure 1F), whereas only MCH II expression in-
creased in myeloid DCs after 14 days (Figure 1G).
As inflammatory cytokines such as TNF-a, IL-6,
and IFN-g have been reported to influence cathepsin
activity in macrophages and DCs [22-24], we
evaluated the association between plasma cytokineprofiles and cathepsin expression in our GVHD
model. Plasma levels of TNF-a, IL-6, and IFN-g
were determined on days 7 and 14 after syngeneic
and allogeneic transplantation (Table 1 and
Figure 2A-C). With the exception of IL-6 at day 14,
all plasma derived from allogeneically transplanted
mice had significantly higher levels of cytokines than
the syngeneic controls. Although both INF-g and
IL-6 were higher 7 days posttransplantation than 14
days posttransplantation, TNF-a levels were increased
between day 7 and day 14. Although IL-6 and IFN-g
may have contributed to the intial increase in cathepsin
S activity, it remains high at 14 days posttransplanta-
tion, whereas levels of these cytokines decrease.
TNF-a levels alone increase from day 7 to day 14
Figure 2. Plasma cytokines 7 days posttransplantation. Plasma cytokines TNF-a, IL-6, and IFN-g present in syngeneic and allogeneic mice 7 days (n5 9)
and 14 days (n5 8) after transplantation. All results are presented as mean6 SEM for a minimum of three mice/group. *** indicates P\.001, **P\.01.
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sins B and L.Cathepsin Activities In Vivo
We have previously shown that therapeutic inter-
ventions that induce decreased in vivo T cell priming
responses to antigens including MiHC correlate with
the ability to inhibit GVHD in murine models [1].
Having shown that cathepsin S is increased in macro-
phages, DCs, and B cells day 7 after transplantation,
we evaluated whether the cathepsin inhibitor LHVS
could affect cathepsin activity in vivo, inhibit T cell
antigen-specific priming to exogenous antigens, and
reduce GVHD. LHVS affects cathepsin activity
in vitro, in a dose-dependent manner, with inhibition
of cathepsin S at lower concentrations (100 nM) and
cathepsin B and L activity at higher concentrations
(.1 mM) (data not shown). LHVS was administered
by i.p. injection three times weekly for 2 weeks fol-
lowed bymeasurement of cathepsin S, B, and L activity
in spleen- and lymph node-derived lymphocytes. As
shown in Figure 3, splenic and lymph node Cathepsin
S activity was significantly decreased in mice treated
with 50 mg and 100 mg/kg LHVS. (Splenocytes
from vehicle-, LHVS50- and LHVS100-treated mice:
208.1 6 15.8, 63.7 6 14.7, 50.9 6 18.1 mUnits/mg,
respectively; lymph nodes from vehicle-, LHVS50-,
and LHVS100-treated mice: 63.2 6 25.4, 14.5 6
7.1, 15.6 6 7.1 mUnit/mg, respectively). Higher con-
centrations of LHVS (100mg/kg) inhibited splenic ca-
thepsin B activity (vehicle, LHVS50, and LHVS100:Table 1. Cytokine Levels in Syngeneic versus Allogeneic Transplan
Day 7
Syngeneic Allogeneic P value Syng
TNF-a 2.1 ± 1.5 110.9 ± 10.7 a 8.4 ±
IL-6 nd 63.6 ± 15.8 b 4.9 ±
IFN-g 2.5 ± 0.9 555.1 ± 84.3 a 2.0 ±
TNF-a, IL-6, and IFN-g were measured in plasma 7 (n5 9) and 14 days (n5 8)
results are presented as mean 6 SEM for a minimum of three mice/group.
aP < .001.
bP < .01.991.66 183.4, 626.66 97.8, 313.86 56.3 mUnit/mg,
respectively) but not cathepsin L.
Effect of LHVS on In Vivo T Cell Priming to
Minor Histocompatibility Antigens in GVHD
Models (C57BL/6 anti-BALB.B)
Studies have shown that LHVS can inhibit exoge-
nous antigen presentation in vitro and in vivo [9,17]. In
preparation for in vivo T cell priming experiments,
we first confirmed the ability of in vivo-administered
LHVS to affect the ability of DCs to present
exogenous antigens. Purified DC (CD11c1) from
mice treated three times weekly with LHVS or
vehicle were removed after 2 weeks of treatment and
evaluated for CD41OT-II transgenic T cell responses
after pulsing with exogenous OVA protein. As shown
in Figure 4A, OT-II CD41 T cell proliferation was
significantly inhibited after pulsing with DC derived
from LHVS-treated mice compared with DC derived
from vehicle-treatedmice in a dose-dependent manner
(vehicle, LHVS50, and LHVS100: 9363 6 520,
3794 6 483, 816 6 136 DCPM). The lower dose of
LHVS, which inhibits cathepsin S only, inhibited the
T cell response to exogenous OVA protein by about
50%, whereas the higher dose of LHVS almost com-
pletely abolished OVA-dependent T cell responses.
Becausemultiple endogenousmiHA are recognized
in GVHD, we next evaluated the effect of LHVS
on a T cell priming response against miHA using the
previously establishedC57BL/6 anti-BALB.BmiHAin-
compatiblemodel (H-2b identical,MiHAdisparate) [1].
This response is dependent on both CD81 and CD41ted Mice
Day 14 Day 7 versus day 14
eneic Allogeneic P value P value
4.6 181.8 ± 29.1 a .03
4.9 25.3 ± 21.1 ns ns
0.9 29.3 ± 5.1 a <.0001
after syngeneic (BB/ BB) or allogeneic (B6/ BB) transplantation. All
Figure 3. In vivo inhibition of splenic and lymph node cathepsin activity with LHVS. Cathepsin S, B, and L activities of spleen (SP) and lymph node (LN)
were measured by quantitation of fluorescent cleavage product as described in the Methods section. Mice were given either 50 mg/kg (gray bar) or 100
mg/kg (white bar) of LHVS or vehicle (black bar) by i.p. injection for 2 weeks (three times per week). All results are presented as mean6 SEM for a min-
imum of three mice/group. ** and * indicate P\.01 and P\.05, respectively.
552 Biol Blood Marrow Transplant 18:546-556, 2012H. Fujii et al.T cells [1,25-27]. C57BL/6micewere administered 100
mg/kg LHVS or vehicle three times weekly for 2 weeks
before intraperitoneal injection of 2.5  107 BALB.B
splenocytes. Administration of LHVS was continued
three times per week for 4 to 8 weeks before evaluating
splenic T cell responses. Splenocytes derived from
C57BL/6 mice were then rechallenged in vitro with
mitomycin C-treated BALB.B stimulators. Primed
C57BL/6 anti-BALB.B T cell responses were signifi-
cantly decreased in the LHVS-treated group compared
with those in the vehicle-treated group (responder B6,
stimulator BALB.B; vehicle 15107 6 2790 DCPM,
LHVS 6396 6 1551 DCPM; P\ .01), whereas treat-
ment of splenocytes from both groups with ConA failed
to induce similar differences in the responder cells
(Figure 4B).
Effect of LHVS Treatment on the Development
of GVHD in anAcuteMurinemiHA-Mismatched
GVHD Model
Having established that LHVS treatment can sig-
nificantly reduce T cell priming to miHA, we evalu-Figure 4. The effect of LHVS treatment in vivo on T cell proliferative response
(5  104/well) purified from OT-II splenocytes and DC isolated from C57BL/6
times weekly for 2 weeks were culturedwith 100 mg/mL ovalbumin protein for 7
harvesting and determination of incorporation levels. (B) C57BL/6 mice were
intraperitoneal injections of BALB.B splenocytes (2 weeks apart). Administratio
at 4 to 8 weeks posttransplantation. Responder C57BL/6 splenocytes were cu
hours. T cell proliferation was measured by [3H] thymidine incorporation as de
dard error of the mean (SEM) bars in stimulated and unstimulated cultures (DC
group containing two to four mice. * and *** indicates P\.05 and P\.001, rated the effect of LHVS treatment on aGVHD
secondary to miHA disparity. Using the C57BL/6/
BALB.B model, BALB.B recipient mice were treated
three times per week with LHVS or an equivalent vol-
ume of vehicle starting 2 weeks before transplantation
to ensure initial inhibition of MHC class II presenta-
tion. Treatment was continued at the identical dosing
and frequency until the end of the experiment. All
transplanted mice achieved complete chimerism in pe-
ripheral blood, confirmed by PCR 14 days after trans-
plantation (data not shown). GVHD was measured by
survival, weight loss, and aGVHD score (Figure 5A-C).
Syngeneic transplanted mice BALB.B/ BALB.B all
survived and had a transient weight loss associated
with the myeloablation as well as a GVHD score as
high as 2 at day 8 (because of the transient weight
loss) before returning to 0. As expected, allogeneic
transplanted mice treated with vehicle all developed
GVHD with significant weight loss, 100% fatality by
day 25, and a rising GVHD score. Of the LHVS-
treated mice, all developed GVHD, and only one
survived until the end of the experiment with severes to exogenous and minor histocompatibility antigens. (A) CD41 T cells
splenocytes (5  104/well) treated with LHVS or vehicle (vehicle) three
2 hours and then pulsed with [3H]thymidine for another 18 hours before
administered 100 mg/kg LHVS as described previously, followed by two
n of LHVS or vehicle was continued three times per week until sacrifice
ltured with stimulating BALB.B splenocytes at an R:S ratio of 4:1 for 96
scribed previously. Data are presented as the mean difference, with stan-
PM). Data shown are the mean of three independent experiments, each
espectively.
Figure 5. Effect of LHVS treatment on development of acute GVHD in
a C57BL/6/ BALB.B miHA mismatch model. BALB.B recipients were
administered 100 mg/kg LHVS or vehicle three times weekly starting 2
weeks before transplantation and continuing until the end of the exper-
iment. After irradiation, recipients were injected with either 8 106 BM
and 2 107 spleen cells from C57BL/6 mice or from BALB.B mice (syn-
geneic control). A group of mice not injected with cells after irradiation
served as an irradiation control. Results are shown as mean6 SEM from
three different experiments; each group consisted of at least six mice at
the time of transplantation. (A) Weight loss (note that at day 57, only
one mouse was still alive in the allogeneic group treated with vehicle).
(B) GVHD score. (C) Survival. Each experiment consisted of groups
of at least six mice from two separate experiments.
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seen in weight loss, survival, or GVHD scores in mice
treated with vehicle versus those treated with LHVS.
These results indicate that (1) LHVS is not more toxic
than the vehicle (DMSO) after transplantation and (2)
that LHVS-mediated cathepsin inhibition does not
prevent the development of aGVHD.
Effect of LHVS Treatment on a CD41
T Cell-Dependent Form of Chronic
GVHD-Like Disease
The inability of LHVS to inhibit development of
GVHD supports the relatively minor role of CD41 T
cell responses in the acute C57BL/6 / BALB.B
model, which appears to be driven mainly by cytokine
release and miHA-reactive donor CD81 T cells
[28-31]. As it has been shown that CD41 T cellsmediate a disease similar to cGVHD in a B10.D2/
BALB/c mismatch model [32-34], we adapted this
method to our GVHD model. T cell-depleted bone
marrowwas used to reduce aGVHD [29], and a cutane-
ous disease similar to chronic human GVHD was
induced in BALB.B mice by transplantation of
CD62L1CD442 naive T cells from C57BL/6 mice.
Splenic extracts of allogenetically transplanted mice
treated with LHVS or vehicle were examined for ca-
thepsin S activity to confirm in vivo inhibition in this
model. As shown in Figure 6A, LHVS significantly
suppressed cathepsin S activity in vivo after BMT
(51.7% 6 4.9% of control; P \ .001, t test).
Figure 6B shows that mice injected with naive CD41
T cells exhibited significant weight loss in comparison
to mice injected with TCD-BM only (P \ .0001,
Mann-Whitney). However, cathepsin S inhibition
with LHVS did not ameliorate symptoms of GVHD
in this model. Serum IFN-g and TNF-a levels in
LHVS- versus vehicle-treated mice measured 14 days
posttransplantation did not differ significantly: IFN-g
10.9 6 2.6 versus 8.2 6 2.1 pg/mL; TNF-a 57.3 6
10.4 versus 47.4 6 14.7, n 5 4 versus 8, respectively.
Mice treated with LHVS lost more weight (P\ .05,
Mann-Whitney) and, 4 weeks posttransplantation, ex-
hibited more mortality (P\ .005, log-rank test). Also,
mice given LHVS instead of vehicle appeared to have
worse skin pathology (although this difference was
not significant) compared with mice given vehicle
(Figure 6B andC). Determination of regulatoryT cells
(Treg) proportions (CD31CD41CD251FoxP31 cells
versus CD31CD41 cells) from the peripheral blood
mice 2 weeks posttransplantation revealed no signifi-
cant differences between LHVS- and vehicle-treated
mice, although the amount of mice surveyed was small
(n5 2-3mice per group; vehicle- versusLVHS-treated
mice: 0.916 0.44 versus 1.246 0.28;%ofCD31 cells).DISCUSSION
In this study, we found that cathepsin S, B, and L
activites were elevated at different time points after
transplantation in mice that develop GVHD
(Figure 1). Elevated cathepsin S activity at day 7 may
be the result of elevated IFN-g, which can increase
cathepsin activity [22-24]; however IFN-g levels
decrease by day 14, whereas cathepsin S remains
elevated, indicating that other factors or cytokines
are involved in the maintenance of high cathepsin S
activity. IFN-g is also known to decrease cathepsin L
activity in macrophages [23], which is consistent with
our observation that cathepsin L is higher after 14
days than after 7 days. Intriguingly, we found that
splenic cathepsin L activity was significantly increased
in allogeneic mice 14 days after transplantation
(Figure 1A). It seems plausible that increased splenic
Figure 6. Effect of LHVS on a na€ıve CD41 T cell-mediated cGVHD model. Irradiated BALB.B recipients were injected with 5  106 C57BL/6 T cell-
depleted BM cells (B6TCDBM) alone or in combination with naive CD4 (CD62Lhigh CD442/low CD252T cells. The recipients were administered either
100 mg/kg of LHVS or an equivalent volume of vehicle three times weekly starting at 2 weeks before transplantation and continuing until the end of the
experiment. (A) Confirmation of cathepsin S inhbition in allogenetically transplanted mice. Mice were treated with 100 mg/kg LHVS or vehicle three
times weekly beginning 14 days before BMTuntil the end of the experiment; splenic cathepsin activity was measured at 14 days post-BMT. (B) Mean
weight loss 6 SEM; weight loss is expressed as a percentage of starting weight. (C) Skin pathology; vehicle, or LHVS-treated recipients were scored
the end point (day 28). (D) Survival curve. These experiments were done twice and results were pooled; all groups consisted of at least five mice.
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antigen, which is supported by previous reports show-
ing foreign antigens elevate active cathepsin L in the
spleen and cathepsin B in DCs [35,36].
GVHD is the result of injury to host tissue caused
by alloreactive donor T cells [37,38]. Memory T cells
are much less efficient than naive T cells at causing
GVHD [34,39-41], suggesting that priming by APCs
in the host is crucial for generation of pathological
T cell populations. GVHD following MHC-
identical HSC transplantation is the result of miHC
disparities following priming of donor-derived T cells
by host or donor-derived APC-presenting host anti-
gen. Priming of naive CD81-T cells, a harbinger of
immune-mediated destruction in GVHD, often re-
quires CD41-T cell help [42]; consequently, blockage
of MHC II with an inhibitory peptide reduces miHC-
disparate GVHD in mice [43]. Alternative methods of
MHCII inhibition for the reduction of GVHD have
been explored. Previously, we have shown that chloro-
quine treatment of mice inhibits T cell responses to
MiHC and reduces the development of a miHC-
disparate model of GVHD [1]. Interpretation of this
data is complicated by the fact that chloroquine can
also suppress proinflammatory cytokine secretion
from APCs in response to stress or innate immune
challenge [44-46] and can block sensing of CpG-
DNA [47,48]. We thus sought to verify the
contribution of MHC II-mediated antigen presenta-
tion to the development of miHC-disparate GVHD
by directly inhibiting cathepsin S.Recent studies have shown that inhibition of
cathepsin S in vivo alters antigen presentation and
immunity and may be useful as a potential therapy
in autoimmune diseases [8,17,18]. However, the
importance of cathepsin S appears to depend on
mouse strains. The role of cathepsin S in the
recognition of endogenous antigens, especially allo-
antigens, is still controversial [8,9]. Although
cathepsin S treatment impaired the ability of C57BL/
6 mice to prime T cell responses against miHA-
incompatible BALB.B splenocytes (Figure 4), it did
not reduce the severity of GVHD in the same model
(Figure 5) or in even a model that relies solely on
CD41-T cells to induce disease (Figure 6). Korngold
et al [49] reported that severe acute CD41 T cell-
mediated GVHD across miHA barrier depends on
the expression of nonhematopoietically, rather than
hematopoietically, derived alloantigens for target-
tissue infiltration and injury in this mice model. This
may explain the discrepancy between the effect of
LHVS in MLR and GVHD.
Experiments in CatS-deficient mice show that the
dependency of antigen presentation on CatS-mediated
Ii-chain degradation can vary with both antigen and
type of APC [8-10]. In the C57BL/6 / BALB.B
aGVHD, despite estimated differences of more than
29 miHA loci between these two strains, the CTL
response is thought to be limited to only a few
immunodominant Ags [50]. Inhibition of CatS may
not affect the particular antigens driving aGVHD in
this model. In addition, inflammatory cytokines
Biol Blood Marrow Transplant 18:546-556, 2012 555Inhibition of Cathepsin S and Allogeneic T Cell Priming in GVHDproduced as a consequence of allogeneic transplanta-
tion may be responsible for much of the pathology in
this acute model. The failure of CatS inhibition to re-
duce the severity of aGVHD despite successfully de-
creasing alloantigen responses may indicate that our
previous reduction of mouse GVHD development
with chloroquine in the samemodel [1] may be because
of choloroquine-mediated inhibition of TLR9 signal-
ing and the ensuing lack of B cell activation. Previous
results in our lab show that GVHD is associated with
a population of B cells that express high levels of
TLR9 and respond to CpG with increased CD86
levels, suggesting that these B cells may be important
APCs in GVHD development [5].
IFN-g produced by donor T cells is thought to be
a central mediator of GVHD (reviewed in [51]); re-
cently, we have shown that early onset cGDHV is as-
sociated with decreased levels of INF-g in humans
[52]. However INF-g and TNF-a are both unlikely
to be significant mediators of exacerbated GVHD af-
ter cathepsin inhibition, as no difference in the serum
levels of these cytokines was observed in the LHVS-
treated versus untreated group. Also, development of
effective Tregs from the naive T cells used to induce
disease could be impeded by LHVS and increase pa-
thology. Although no differences were observed in
the relative amounts of Tregs between the two groups,
a definite conclusion regarding Treg involvement
would require functional assays. A recent article indi-
cates that blocking Cathepsin S activity may increase
the amount of endosomal peptides cross-presented
on MHCI [53], which could interact with newly
formed CD81 T cells. Such an effect may speed up
the insidious onset of the cGVHD-like model. Fur-
ther experiments are needed to clarify the mechanisms
behind these observations, and as we cannot rule out
off-target effects of LHVS, these observations should
be confirmed with alternative Cathepsin S inhibitors.
A model that has a less rapid deterioration of the
LHVS-treated mice and that allows distinction of do-
nor and recipient cells would be more suited for mech-
anistic studies. Pharmacologically viable cathepsin S
inhibitors are sought after for their potential of thera-
peutics in a wide range of diseases. Of the many devel-
oped, only a few have shown promise in preclinical or
clinical trials [54]. However, some have emerged in the
past few years and are being clinically evaluated for
treatment of arthritis and pancreatic cancer (reviewed
in [54]); prophylaxis or treatment of GVHD with
these inhibitors should be approached with caution.ACKNOWLEDGMENTS
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